- Home
- STKS vs NRXP Comparison
STKS vs NRXP Comparison
Compare STKS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STKS | NRXP |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.3M | 70.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | STKS | NRXP |
|---|---|---|
| Price | $2.26 | $2.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.38 | ★ $30.67 |
| AVG Volume (30 Days) | 42.3K | ★ 1.8M |
| Earning Date | 03-09-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $820,588,000.00 | $242,000.00 |
| Revenue This Year | $25.55 | N/A |
| Revenue Next Year | $6.27 | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 51.57 | N/A |
| 52 Week Low | $1.70 | $1.58 |
| 52 Week High | $5.26 | $3.84 |
Technical Indicators
Market Signals| Indicator | STKS | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 39.99 |
| Support Level | $2.26 | $2.13 |
| Resistance Level | $2.41 | $2.38 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 42.47 | 15.59 |
Price Performance
Historical ComparisonAbout STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.